Inyx Inc
OTC:IYXI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its Industry Average (3.8), the stock would be worth $0 (100% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0 | $0 |
0%
|
| Industry Average | 3.8 | $0 |
-100%
|
| Country Average | 2.5 | $0 |
-100%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
I
|
Inyx Inc
OTC:IYXI
|
53.1 USD | -0 | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
825.8B USD | 30.4 | 39.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
548.5B USD | 6.7 | 26.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 5.8 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 5.9 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.3B USD | 5.2 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 5.9 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 1.7 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.3B USD | 6.3 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Inyx Inc
Glance View
Inyx, Inc. is pharmaceutical company, which develops and acquires niche pharmaceutical products and drug delivery systems for key therapeutic areas, including respiratory and dermatological applications. The company is headquartered in New York City, New York and currently employs 572 full-time employees. The company went IPO on 2003-02-19. Its operations are focused on the development of both prescriptions, over the counter pharmaceutical products, and specialty consulting services. Also, the Company utilizes niche drug delivery capabilities to develop its own products. The product and service categories of the Company include Metered Dose Inhalers (MDIs) (CFC & HFA), Dry Powder Inhalers (DPIs), Metered Dose Pump Sprays (nasal and oral), Hydrocarbon Foam Aerosols, Saline Aerosols, Sterile Solutions/Injectables, Solid Dose, Formulation Services, Analytical Development Validation, Stability Services, Regulatory Support and Integrated Project Management.
